Postcode prescribing is alive and well in ScotlandBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7355.101/a (Published 13 July 2002) Cite this as: BMJ 2002;325:101
- David Cameron, senior lecturer in medical oncology,
- J Michael Dixon, consultant breast surgeon
- University of Edinburgh and Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU
- Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU
EDITOR—We had understood that one of the intentions of the National Institute for Clinical Excellence (NICE) was to rationalise the introduction of new drugs and technologies across the United Kingdom so that NHS patients would have equitable access. This has plainly not happened. We illustrate the problem with three recently licensed drugs, imatinib, irinotecan, and trastuzumab.
Imatinib has yet to be appraised by the National Institute for Clinical Excellence, but our local haematologists completed the paperwork for approval by Lothian Health Board's drug …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial